hCG (Human Chorionic Gonadotropin): Physiology and What Research Reports

What hCG Is

Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of two non-covalently associated subunits — an alpha subunit shared with luteinising hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone, and a beta subunit that gives hCG its distinct identity — as set out in a 2018 review of hCG as a regulator of gestation and cancer (PMID 29772831). Because hCG is a large, heavily glycosylated molecule rather than a short amino-acid chain, endocrinology texts classify it as a protein (glycoprotein) hormone; the term "hCG peptide" circulates informally in peptide-focused reading, but the molecule itself is not a small research peptide, and the verified literature summarised here treats it as a hormone studied in reproductive endocrinology and laboratory medicine.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, test result or treatment. Nothing here describes how hCG is administered, and no protocol, schedule or quantity is suggested.

Where hCG Is Produced

The 2018 review described hCG as being produced predominantly by placental trophoblast — the syncytiotrophoblast layer — where its concentrations rise early in gestation and where it functions as an endocrine signal supporting pregnancy (PMID 29772831). The same review reported that hCG and hCG-related molecules are also expressed by trophoblastic and non-trophoblastic tumours, which is why the hormone appears both in obstetric physiology and in oncology literature (PMID 29772831).

What hCG Does in the Body

The 2018 review reported that hCG signals through the shared LH/hCG receptor, a G-protein-coupled receptor expressed in gonadal tissue and also documented at non-gonadal sites including the uterus, and that this receptor distribution underlies the hormone's broad range of described actions (PMID 29772831). Among those actions, the review described maintenance of the corpus luteum and its progesterone output in early pregnancy, plus roles in implantation, local immune modulation, angiogenesis and trophoblast invasion (PMID 29772831).

Uterine muscle: what an in vitro study reported

Direct action on uterine smooth muscle has been examined experimentally: an in vitro study applied hCG to human myometrial tissue and reported that the hormone modulated the contractility of the isolated muscle preparations (PMID 20973655). That design — isolated tissue in an organ bath — tests pharmacological responsiveness of the tissue, and the study did not evaluate clinical outcomes in pregnant patients (PMID 20973655). Read alongside the receptor-distribution work, researchers have used such findings to discuss why a placental hormone might influence the organ in which it is produced (PMID 29772831).

How hCG Is Measured and Studied

Most published hCG data come from immunoassays of serum or urine. A 2023 analysis of hCG reporting examined the lack of uniformity in how laboratories name, calibrate and report hCG results, and called for standardisation so that values can be compared across methods and institutions (PMID 36684490). That paper is a useful reminder that an "hCG level" is assay-dependent: different platforms may recognise intact hormone, free beta subunit and degradation products to different degrees, which is exactly why the authors argued for consistent reporting practice (PMID 36684490).

Interference and unexpected results

Two case-based papers in this set illustrate how hCG measurement can mislead. A 2022 case report described an elevated hCG concentration in a patient after an unsuccessful in vitro fertilisation cycle and worked through the laboratory investigation of that discordant result (PMID 35777793). A 2025 report described false-positive hCG testing occurring in association with an upper urinary tract infection, a scenario in which urine findings did not reflect pregnancy (PMID 40023768). Both reports reinforce the standardisation argument made in the reporting analysis: interpretation depends on the assay, the specimen and the clinical context (PMID 36684490).

hCG in Oncology Research

Beyond pregnancy, the 2018 review discussed hCG and its beta subunit as markers and potential mediators in cancer biology, describing expression by trophoblastic disease and by a range of non-trophoblastic tumours (PMID 29772831). The review framed hCG as an endocrine regulator whose signalling pathways overlap between gestational and malignant tissue, rather than as a treatment (PMID 29772831).

Safety and Adverse Events: What Studies Report

The verified papers assembled for this entry are physiology, review and laboratory-medicine publications; none of them is a safety trial, and none reports adverse-event rates, tolerability data or dose-related harms in humans. What this literature does document is a measurement hazard rather than a pharmacological one: false-positive hCG results have been reported in the context of an upper urinary tract infection (PMID 40023768), and an unexpectedly elevated hCG concentration has been reported after an unsuccessful in vitro fertilisation cycle (PMID 35777793). The reporting analysis argued that inconsistent units and calibration across laboratories compound that risk of misinterpretation (PMID 36684490). Readers looking for an adverse-event profile will not find one in these sources; prescribing information and dedicated clinical safety studies are the appropriate places for that question.

Regulatory Context

In the United States, hCG products for injection are prescription-only medicines with approved labelling for specified reproductive and endocrine indications, and regulators have acted against over-the-counter preparations marketed as "hCG" for weight reduction, which are not approved for that purpose. This is regulatory context, not legal advice.

Limitations of This Summary

• The evidence cited here is limited to one review, one in vitro tissue study, two case reports and one laboratory reporting analysis — it is not a systematic review of hCG.
• Findings from isolated human myometrial tissue reported in vitro do not translate automatically to intact physiology (PMID 20973655).
• Case reports describe individual patients and cannot establish how often unexpected or false-positive hCG results occur (PMID 35777793).
• No quantities, schedules or administration details are discussed on this page because the verified sources do not support them.

References

• Human Chorionic Gonadotropin (hCG)-An Endocrine, Regulator of Gestation and Cancer (International Journal of Molecular Sciences, 2018)
• In vitro activity of human chorionic gonadotropin (hCG) on myometrium contractility (Gynecological Endocrinology, 2011)
• Elevated hCG Concentration in a Patient after an Unsuccessful in vitro Fertilization (Annals of Clinical and Laboratory Science, 2022)
• A Search for Uniformity in Human Chorionic Gonadotropin (hCG) Reporting (Indian Journal of Clinical Biochemistry, 2023)
• False positive hCG testing and upper urinary tract infection (Hormone Molecular Biology and Clinical Investigation, 2025)